Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1954 1
1955 1
1961 1
1969 2
1972 1
1976 2
1985 3
1986 1
1987 2
1989 3
1990 3
1992 1
1993 3
1994 4
1995 5
1996 3
1997 1
1998 7
1999 6
2000 5
2001 14
2002 10
2003 4
2004 11
2005 11
2006 13
2007 12
2008 11
2009 9
2010 12
2011 13
2012 23
2013 17
2014 20
2015 22
2016 25
2017 24
2018 36
2019 29
2020 29
2021 43
2022 57
2023 59
2024 60
2025 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

612 results

Results by year

Filters applied: . Clear all
Page 1
Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. Among authors: bateman rj. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
Alzheimer's disease.
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Masters CL, et al. Among authors: bateman r. Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56. Nat Rev Dis Primers. 2015. PMID: 27188934 Free article. Review.
Biomarker-based staging of Alzheimer disease: rationale and clinical applications.
Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, Karikari TK, Apostolova L, Murray ME, Verberk I, Vogel JW, La Joie R, Gauthier S, Teunissen C, Rabinovici GD, Zetterberg H, Bateman RJ, Scheltens P, Blennow K, Sperling R, Hansson O, Jack CR Jr, Rosa-Neto P. Therriault J, et al. Among authors: bateman rj. Nat Rev Neurol. 2024 Apr;20(4):232-244. doi: 10.1038/s41582-024-00942-2. Epub 2024 Mar 1. Nat Rev Neurol. 2024. PMID: 38429551 Review.
Modeling late-onset Alzheimer's disease neuropathology via direct neuronal reprogramming.
Sun Z, Kwon JS, Ren Y, Chen S, Walker CK, Lu X, Cates K, Karahan H, Sviben S, Fitzpatrick JAJ, Valdez C, Houlden H, Karch CM, Bateman RJ, Sato C, Mennerick SJ, Diamond MI, Kim J, Tanzi RE, Holtzman DM, Yoo AS. Sun Z, et al. Among authors: bateman rj. Science. 2024 Aug 2;385(6708):adl2992. doi: 10.1126/science.adl2992. Epub 2024 Aug 2. Science. 2024. PMID: 39088624 Free PMC article.
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. McDade E, et al. Among authors: bateman rj. Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Alzheimers Res Ther. 2022. PMID: 36544184 Free PMC article. Clinical Trial.
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Bateman RJ, et al. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. N Engl J Med. 2012. PMID: 22784036 Free PMC article.
Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid.
Drieu A, Du S, Storck SE, Rustenhoven J, Papadopoulos Z, Dykstra T, Zhong F, Kim K, Blackburn S, Mamuladze T, Harari O, Karch CM, Bateman RJ, Perrin R, Farlow M, Chhatwal J; Dominantly Inherited Alzheimer Network; Hu S, Randolph GJ, Smirnov I, Kipnis J. Drieu A, et al. Among authors: bateman rj. Nature. 2022 Nov;611(7936):585-593. doi: 10.1038/s41586-022-05397-3. Epub 2022 Nov 9. Nature. 2022. PMID: 36352225 Free PMC article.
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS.
Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ. Lucey BP, et al. Among authors: bateman rj. Ann Neurol. 2023 Jul;94(1):27-40. doi: 10.1002/ana.26641. Epub 2023 Apr 20. Ann Neurol. 2023. PMID: 36897120 Free PMC article. Clinical Trial.
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD, Jiang H, Strandberg O, Pichet Binette A, Palmqvist S, Sato C, Sachdev P, Koyama A, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Mattsson-Carlgren N, Stomrud E, Ossenkoppele R, Schindler SE, Hansson O, Bateman RJ. Horie K, et al. Among authors: bateman rj. Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z. Epub 2023 Jul 13. Nat Med. 2023. PMID: 37443334 Free PMC article.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Free PMC article. Clinical Trial.
612 results